Castle Biosciences(CSTL)
$32.98+0.23 (+0.70%)
CSTL
Castle Biosciences financials statements
$32.98
At close:+0.23 (+0.70%)
Want to see CSTL full AI Analyst Report?
Castle Biosciences (CSTL) Ratios
474 Followers
Castle Biosciences Ratios
CSTL's free cash flow for Q3 2026 was $12.25M. For the 2026 fiscal year, CSTL's free cash flow was decreased by $-7.49M and operating cash flow was $19.74M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.26 | 7.29 | 6.20 | 8.09 | 14.21 |
| Quick Ratio | 5.11 | 7.13 | 6.04 | 7.98 | 14.13 |
| Cash Ratio | 1.70 | 2.42 | 2.07 | 3.40 | 13.25 |
| Solvency Ratio | 0.15 | 0.45 | -0.73 | -1.17 | -0.55 |
| Operating Cash Flow Ratio | 0.94 | 1.31 | -0.12 | -1.15 | -0.76 |
| Short-Term Operating Cash Flow Coverage | 154.31 | 233.33 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 253.41M | $ 284.75M | $ 233.56M | $ 244.11M | $ 302.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.05 | 0.03 | 0.03 | 0.02 |
| Debt-to-Equity Ratio | 0.08 | 0.06 | 0.04 | 0.03 | 0.02 |
| Debt-to-Capital Ratio | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.23 | 1.17 | 1.16 | 1.12 | 1.12 |
| Debt Service Coverage Ratio | 33.20 | 40.72 | -4102.27 | -3328.12 | -27884.00 |
| Interest Coverage Ratio | -497.79 | 15.03 | -6179.73 | -4285.59 | -40079.00 |
| Debt to Market Cap | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.28 | 0.97 | 0.57 | 0.51 | 0.33 |
| Net Debt to EBITDA | -7.04 | -2.45 | 1.85 | 1.88 | 8.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% |
| EBIT Margin | -8.55% | 6.67% | -26.10% | -50.27% | -42.53% |
| EBITDA Margin | 3.30% | 11.48% | -20.49% | -42.57% | -38.91% |
| Operating Profit Margin | -12.44% | 2.61% | -30.93% | -53.16% | -42.60% |
| Pretax Profit Margin | -8.57% | 6.49% | -26.10% | -50.28% | -42.53% |
| Net Profit Margin | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% |
| Continuous Operations Profit Margin | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% |
| Net Income Per EBT | 81.85% | 84.61% | 100.18% | 97.44% | 78.21% |
| EBT Per EBIT | 68.94% | 248.72% | 84.39% | 94.58% | 99.83% |
| Return on Assets (ROA) | -4.18% | 3.43% | -12.68% | -15.01% | -6.76% |
| Return on Equity (ROE) | -5.13% | 4.00% | -14.69% | -16.82% | -7.60% |
| Return on Capital Employed (ROCE) | -8.40% | 1.80% | -16.76% | -17.72% | -9.16% |
| Return on Invested Capital (ROIC) | -6.85% | 1.52% | -16.71% | -17.19% | -7.14% |
| Return on Tangible Assets | -5.04% | 4.29% | -17.10% | -20.92% | -8.37% |
| Earnings Yield | -2.14% | 2.46% | -9.94% | -10.95% | -2.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.93 | 6.48 | 5.74 | 5.84 | 5.44 |
| Payables Turnover | 3.80 | 8.72 | 4.38 | 6.77 | 6.21 |
| Inventory Turnover | 6.93 | 7.40 | 5.66 | 8.04 | 7.83 |
| Fixed Asset Turnover | 3.07 | 5.30 | 5.82 | 5.17 | 5.57 |
| Asset Turnover | 0.59 | 0.63 | 0.48 | 0.31 | 0.20 |
| Working Capital Turnover Ratio | 1.14 | 1.19 | 0.87 | 0.47 | 0.26 |
| Cash Conversion Cycle | 2.54 | 63.78 | 44.73 | 53.96 | 54.93 |
| Days of Sales Outstanding | 46.00 | 56.30 | 63.61 | 62.53 | 67.05 |
| Days of Inventory Outstanding | 52.69 | 49.32 | 64.44 | 45.38 | 46.62 |
| Days of Payables Outstanding | 96.15 | 41.84 | 83.32 | 53.95 | 58.73 |
| Operating Cycle | 98.69 | 105.62 | 128.05 | 107.91 | 113.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.22 | 2.34 | -0.21 | -1.60 | -0.76 |
| Free Cash Flow Per Share | 0.98 | 1.32 | -0.72 | -1.81 | -0.89 |
| Dividend Paid and CapEx Coverage Ratio | 1.79 | 2.29 | -0.41 | -7.40 | -5.45 |
| Capital Expenditure Coverage Ratio | 1.79 | 2.29 | -0.41 | -7.40 | -5.45 |
| Operating Cash Flow Coverage Ratio | 1.74 | 2.46 | -0.37 | -3.11 | -2.31 |
| Operating Cash Flow to Sales Ratio | 0.19 | 0.20 | -0.03 | -0.30 | -0.20 |
| Free Cash Flow Yield | 2.51% | 4.94% | -3.33% | -7.71% | -2.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -46.87 | 40.57 | -10.06 | -9.14 | -34.44 |
| Price-to-Sales (P/S) Ratio | 3.28 | 2.23 | 2.63 | 4.48 | 11.45 |
| Price-to-Book (P/B) Ratio | 2.39 | 1.62 | 1.48 | 1.54 | 2.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 39.81 | 20.26 | -30.05 | -12.97 | -47.97 |
| Price-to-Operating Cash Flow Ratio | 17.52 | 11.41 | -102.81 | -14.72 | -56.77 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | -0.31 | 0.59 | -0.08 | -0.27 |
| Enterprise Value Multiple | 92.37 | 16.96 | -10.99 | -8.63 | -20.66 |
| Enterprise Value | 1.05B | 646.87M | 494.88M | 503.76M | 756.19M |
| EV to EBITDA | 92.37 | 16.96 | -10.99 | -8.63 | -20.66 |
| EV to Sales | 3.04 | 1.95 | 2.25 | 3.68 | 8.04 |
| EV to Free Cash Flow | 36.99 | 17.70 | -25.71 | -10.65 | -33.66 |
| EV to Operating Cash Flow | 16.28 | 9.97 | -87.96 | -12.09 | -39.84 |
| Tangible Book Value Per Share | 12.81 | 12.59 | 10.22 | 10.47 | 12.84 |
| Shareholders’ Equity Per Share | 16.24 | 16.41 | 14.60 | 15.32 | 16.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.15 | -0.00 | 0.03 | 0.22 |
| Revenue Per Share | 11.88 | 11.96 | 8.20 | 5.26 | 3.74 |
| Net Income Per Share | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 |
| Tax Burden | 0.82 | 0.85 | 1.00 | 0.97 | 0.78 |
| Interest Burden | 1.00 | 0.97 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.15 | 0.16 | 0.24 | 0.33 | 0.32 |
| SG&A to Revenue | 0.67 | 0.60 | 0.30 | 0.41 | 0.00 |
| Stock-Based Compensation to Revenue | 0.13 | 0.15 | 0.23 | 0.27 | 0.23 |
| Income Quality | -2.66 | 3.56 | 0.10 | 0.62 | 0.61 |
Currency in USD

